Could a daily probiotic boost your immune defenses?
NCT ID NCT05632341
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a probiotic supplement called GCWB1176 in 100 adults with normal or slightly low white blood cell counts. Participants took either the supplement or a placebo daily for 8 weeks. Researchers measured changes in natural killer (NK) cell activity and other immune markers to see if the supplement could improve immune function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lactococcus lactis (a probiotic supplement)
- What this could lead to
- If it works, this could point toward a simple daily supplement to help support the immune system, potentially reducing the frequency of common colds or infections.
- What could go wrong
- This is a small, early-stage trial with only 100 participants, and results may not apply to everyone. The supplement may show no significant benefit over placebo, and individual results can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Mar 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. At the time of screening, 19 or 75 years 2. A person with a peripheral blood leukocyte level measured in Visit 1, 3x10\^3 cells/μl or more, 8x10\^3 cells/μl 3. Those who are more than one of the following standards * Those who had more than twice within one year of visiting 1 year. * {Common cold, acute tonsillitis, acute pharyngitis, acute laryngitis, acute rhinitis, etc. * Those who have stomatitis more than twice within 1 year of visit * Those who had Herpes Zoster infection within 1 year of visit 4. Those with a stress awareness scale (PSS) 16 or more 5. A person who agrees to participate in this human application test before the start of the human test and writes a written consent form Exclusion Criteria: 1. Those who are currently treating drugs due to underlying disease, etc. 2. Hypertension patients (systolic blood pressure 140 mmHg or higher or dichotomous blood pressure 90 mmHg or higher, human application test target 10 minutes stabilized) 3. Patients with diabetes with an fasting blood sugar at least 126 mg/dL or administering urine disease (oral blood sugar, insulin, etc.) 4. Those who are 0.1 UIU/mL or less, or 10 UIU/mL or more 5. Those who have vaccinated vaccines (influenza, corona, shingles that can affect immunity) within 3 months of visiting 1 6. A disease that can affect immune responses such as adult -like and rhinitis 7. AST (GOT) or ALT (GPT) is three times more than the normal upper limit of the embodiment 8. Those who are 1.5 times more than the normal upper limit of Creatinine 9. Those who administered steroids, antibiotics, immunosuppressants, and gastric acid inhibitors within 1 month of visit. 10. Visit 1 person who consumes vitamins, health functional foods that can affect immunity within 2 weeks of visiting 11. A person who has administered or consumed lactic acid bacteria products (4 or more times a week) within 2 weeks of visiting within 2 weeks of visit. 12. Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion 13. Those who are pregnant or have a planning plan for lactation or this human application period 14. Those who have participated in other interventional clinical trials (including human application test) within 8 weeks of visit, or plan to participate in other interventional clinical trials (including human application tests) after the beginning of this human application test 15. Those who are sensitive or allergic to food ingredients for this human application 16. Those who have a BMI (body mass index) of 30 kg/m2 or more 17. A person who consumed alcohol within 1 month (30 days) based on 1 visit (man\> 210 g/week, woman\> 140 g/week) 18. Those who judge that the test person is inadequate for other reasons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immune function are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul St. Mary's Hospital, College of Medicine
Seoul, South Korea
-
St. Vincent's Hospital, College of Medicine
Suwon, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A daily yogurt drink might strengthen your immune defenses
- Ancient gold remedy put to the test for Children's immune health
- Probiotic pill may shield elite footballers from travel gut troubles
- Ketone drink tested to fight frailty in seniors
- Ice baths vs cold showers: which is better for your health?
- Probiotic pill shows promise for immune boost in healthy adults